Brain‐targeted co‐delivery of β‐amyloid converting enzyme 1 shRNA and epigallocatechin‐3‐gallate by multifunctional nanocarriers for Alzheimer's disease treatment,IUBMB Life

当前位置： X-MOL 学术 › IUBMB Life › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Brain‐targeted co‐delivery of β‐amyloid converting enzyme 1 shRNA and epigallocatechin‐3‐gallate by multifunctional nanocarriers for Alzheimer's disease treatment
IUBMB Life ( IF 4.6 ) Pub Date : 2020-07-15 , DOI: 10.1002/iub.2330
Lijie Lv ₁ , Fan Yang ₂ , He Li ₃ , Jiuli Yuan ₁

Affiliation

Progressive memory loss and cognitive dysfunction are hallmark clinical features of Alzheimer's disease (AD). As a possible treatment for AD, we developed an epigallocatechin‐3‐gallate (EGCG) and β‐site amyloid precursor protein (APP) cleaving enzyme 1 antisense (BACE1‐AS) shRNA‐encoded plasmid. The plasmid was loaded on to RVG29 peptide‐targeted multifunctional nanoparticles (NPs) (REGS‐PN). The polymeric NPs were characterized by flow cytometry, biocompatibility assay, pharmacokinetic analysis, Western blot analysis, and the Morris water maze (MWM) test. The differences in plasma and brain NP accumulation following intravenous administration showed a significantly longer circulation time for EGS‐PN and REGS‐PN in the blood stream. In contrast, free EGCG was rapidly eliminated from the circulation. REGS‐PM successfully travelled through the blood–brain barrier and was present at a higher concentration in the brain compared with both non‐targeted NPs and free EGCG. REGS‐PN administration to APPswe/PS1dE9 double transgenic mice (APP/PS1 mice) resulted in downregulation of the key enzyme in amyloid‐β formation (BACE1) and amyloid beta, indicating synergistic therapeutic activity. The MWM test revealed that simultaneous delivery of a therapeutic gene and EGCG (REGS‐PN) remarkably improved the spatial learning and memory capabilities of APP/PS1 mice as well as wild type mice compared with the free EGCG‐treated group. With these results, we propose that co‐delivery of a therapeutic gene (shRNA) and EGCG in a multifunctional nanocarrier could achieve higher therapeutic concentrations in the brain and could be an excellent strategy for AD treatment.

更新日期：2020-07-15

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>